Compare Virgin Galactic Holdings, Inc. (SPCE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs TG Therapeutics Inc — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.97 (market cap $498.02M), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 15.3× Virgin Galactic Holdings, Inc.'s market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| SPCE | TGTX | |
|---|---|---|
Market Cap | $498.02M | $7.64B |
Sector | Industrials | Health |
52-Week High | $7.52 | $59.06 |
52-Week Low | $2.17 | $26.94 |
Enterprise Value | $597.87M | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.26, up 0.77% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company continues to face significant fundamental challenges with negative profit margins (-19,781.3% net income margin) and declining revenue, though recent earnings have consistently beaten expectations. Cash flow remains negative but shows improvement trend from -$207M in 2022 to -$35M in 2025.
While technical momentum appears positive, SPCE's fundamental weakness and high cash burn present substantial risks. The stock offers speculative appeal for investors betting on space tourism commercialization, but requires careful risk management given persistent losses and competitive pressures in the emerging space sector.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
